Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACU-4429 in Subjects With Geographic Atrophy

• Status: Completed
• Trial end date: 2012-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of the investigational drug ACU-4429 in subjects with geographic atrophy.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Acucela Inc.; Kubota Vision Inc.
• Collaborator: Otsuka Pharmaceutical Co., Ltd.

Criteria

Inclusion Criteria:

• Have a clinical diagnosis of geographic atrophy, as defined in the protocol

Exclusion Criteria:

• Currently receiving or has received a medication prohibited by the protocol